We are live on ! Find out more
6CM

683 Capital Management Portfolio holdings

AUM $2.04B
1-Year Est. Return 94.26%
This Fund
S&P 500
This Quarter Est. Return
+21.35%
1 Year Est. Return
+94.26%
3 Year Est. Return
+310.51%
5 Year Est. Return
+306.13%
10 Year Est. Return
+3,783.92%
AUM
$2.04B
AUM Growth
+$120M
Cap. Flow
-$149M
Cap. Flow %
-7.33%
Top 10 Hldgs %
47.27%
Holding
257
New
21
Increased
32
Reduced
47
Closed
104

Top Buys

Rank Stock Value
1
U icon
Unity
U
+$16.4M
2
TRAX
First Tracks Biotherapeutics
TRAX
+$14M
3
SE icon
Sea Limited
SE
+$11.9M
4
NU icon
Nu Holdings
NU
+$10.1M
5
GOSS icon
Gossamer Bio
GOSS
+$9.54M

Top Sells

Rank Stock Value
1
ASTH icon
Astrana Health
ASTH
+$17.6M
2
LLY icon
Eli Lilly
LLY
+$15.3M
3
GXO icon
GXO Logistics
GXO
+$14.8M
4
FOLD
Amicus Therapeutics
FOLD
+$11.2M
5
APLS
Apellis Pharmaceuticals
APLS
+$10.1M

Sector Composition

Rank Sector Weight
1 Miscellaneous 48.9%
2 Healthcare 24.5%
3 Financials 7.3%
4 Consumer Discretionary 7.28%
5 Technology 2.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FGII
101
FG Imperii Acquisition Corp
FGII
$290M
$1.99M 0.1%
200,000
– –
LEGO
102
Legato Merger Corp IV
LEGO
$312M
$1.98M 0.1%
200,000
– –
PANL icon
103
Pangaea Logistics
PANL
$543M
$1.95M 0.1%
300,000
-9,500
-3% -$72.1K
COIN icon
104
Coinbase
COIN
$46.1B
$1.9M 0.09%
+13,000
New +$2.35M
AMRZ
105
Amrize Ltd
AMRZ
$22.4B
$1.87M 0.09%
35,000
– –
HDSN
106
Hudson Technologies
HDSN
$224M
$1.87M 0.09%
325,000
– –
MSLE
107
Satellos Bioscience
MSLE
$213M
$1.79M 0.09%
230,833
– –
AMLX icon
108
CALL
Amylyx Pharmaceuticals
AMLX
$3.61B
$1.73M 0.09%
96,600
– –
RARE icon
109
PUT
Ultragenyx Pharmaceutical
RARE
$1.41B
$1.67M 0.08%
+50,000
New +$1.24M
BLUW
110
Blue Water Acquisition Corp III
BLUW
$335M
$1.55M 0.08%
150,000
– –
MAIA icon
111
MAIA Biotechnology
MAIA
$80.9M
$1.54M 0.08%
1,066,666
– –
EVAC
112
EQV Ventures Acquisition Corp II
EVAC
$602M
$1.53M 0.08%
150,000
– –
HEPS
113
D-Market Electronic Services & Trading
HEPS
$947M
$1.46M 0.07%
+500,000
New +$1.38M
PYXS icon
114
Pyxis Oncology
PYXS
$282M
$1.38M 0.07%
459,367
-436,896
-49% -$835K
TMDX icon
115
PUT
Transmedics
TMDX
$3B
$1.33M 0.07%
20,000
– –
WLII
116
Willow Lane Acquisition Corp II
WLII
$1.28M 0.06%
+125,000
New +$1.26M
PMN icon
117
ProMIS Neurosciences
PMN
$129M
$1.25M 0.06%
95,000
+2,150
+2% +$23.3K
LWAC
118
LightWave Acquisition Corp
LWAC
$310M
$1.02M 0.05%
100,000
– –
INAB icon
119
IN8bio
INAB
$10.6M
$1.02M 0.05%
724,637
– –
CDLX icon
120
Cardlytics
CDLX
$25.1M
$898K 0.04%
200,000
+55,000
+38% +$411K
OYSE
121
Oyster Enterprises II Acquisition Corp
OYSE
$352M
$772K 0.04%
75,000
– –
CAE icon
122
CAE Inc
CAE
$7.74B
$627K 0.03%
25,000
– –
GPK icon
123
Graphic Packaging
GPK
$2.82B
$606K 0.03%
57,322
-460,356
-89% -$4.7M
GUTS icon
124
Fractyl Health
GUTS
$102M
$601K 0.03%
756,715
-5,970,520
-89% -$4.25M
MODD icon
125
Modular Medical
MODD
$22.9M
$585K 0.03%
130,000
+4,999
+4% +$22.8K
3 4
5
6 7

Similar funds

SFI
Siemens Fonds Invest Munich, Germany $2.04B AUM 40.78% 1-Year Est. Return
UF
Univest Financial Souderton, Pennsylvania $2.04B AUM 33.06% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $2.04B AUM 35.27% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
C
Certuity North Palm Beach, Florida $2.03B AUM 88.59% 1-Year Est. Return
EF
Evanson Financial Mclean, Virginia $2.04B AUM
JCM
Jacobi Capital Management Pittston, Pennsylvania $2.04B AUM 26.26% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $2.03B AUM 17.65% 1-Year Est. Return

683 Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, 683 Capital Management held 257 positions worth $2.04B, up 6.3% from $1.92B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

683 Capital Management withdrew a net $149M in Q2 2026, closing 104 positions and reducing 47 holdings. Its most notable exit was Eli Lilly, an estimated $15.3M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 49% of assets, up from 47% a quarter earlier, followed by Healthcare and Financials.

Against the trend, 683 Capital Management opened a new position in Unity worth $17.6M.

  • 683 Capital Management's largest Q2 2026 buy was Unity: 615,000 shares worth $17.6M.
  • 683 Capital Management added most to Gossamer Bio in Q2 2026, an estimated $9.54M increase.
  • 683 Capital Management's biggest Q2 2026 reduction was Astrana Health, cutting an estimated $17.6M.
  • 683 Capital Management fully exited Eli Lilly in Q2 2026, selling an estimated $15.3M.
  • 683 Capital Management's ten largest holdings make up 47% of its $2.04B portfolio in Q2 2026.
  • 683 Capital Management opened 21 new positions and closed 104 in Q2 2026.
  • 683 Capital Management's portfolio value rose 6.3% quarter-over-quarter to $2.04B.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.